Skip to main content
Top
Published in: BMC Infectious Diseases 1/2009

Open Access 01-12-2009 | Research article

Moraxella catarrhalisacquisition, airway inflammation and protease-antiprotease balance in chronic obstructive pulmonary disease

Authors: Ganapathi I Parameswaran, Catherine T Wrona, Timothy F Murphy, Sanjay Sethi

Published in: BMC Infectious Diseases | Issue 1/2009

Login to get access

Abstract

Background

Moraxella catarrhalis causes approximately 10% of exacerbations in chronic obstructive pulmonary disease (COPD) and also colonizes the lower airway in stable patients. Little is known about the effects of colonization by M. catarrhalis on airway inflammation and protease-antiprotease balance, and how these changes compare to those seen during exacerbations. Since COPD is a progressive inflammatory disease, elucidating the effects of bacterial colonization and exacerbation on airway inflammation is relevant to understanding disease progression in COPD. Our aims were (1) Analyze changes in airway inflammation in colonization and exacerbation of COPD due to M. catarrhalis; (2) Explore protease-antiprotease balance in colonization and exacerbation due to M. catarrhalis. Our hypothesis were (1) Acquisition of a new strain of M. catarrhalis in COPD increases airway inflammation from baseline and alters the protease-antiprotease balance towards a more proteolytic environment; (2) These changes are greater during exacerbations associated with M. catarrhalis as compared to colonization.

Methods

Thirty-nine consecutive COPD patients with 76 acquisitions of a new strain of M. catarrhalis over a 6-year period were identified in a prospective study. Seventy-six pre-acquisition sputum supernatant samples, obtained just before acquisition of M catarrhalis, and 76 acquisition samples (34 were associated with exacerbation, 42 with colonization) were analyzed for IL-8, TNF-α, Neutrophil Elastase (NE) and Secretory leukocyte protease inhibitor (SLPI). Changes were compared in paired samples from each patient.

Results

IL-8, TNF-α and NE were significantly elevated after acquisition of M. catarrhalis, compared to pre-acquisition samples (p =< 0.001 for all three). These changes were present in colonization (p = 0.015 for IL-8; p =< 0.001 for TNF-α and NE) as well as in exacerbation (p =< 0.001 for all three), compared to pre-acquisition levels. SLPI was significantly lower after acquisition (p =< 0.001), in colonization (p =< 0.001) as well as in exacerbation (p = 0.004), compared to pre-acquisition levels. SLPI levels correlated negatively with NE levels (R2 = 0.07; p = 0.001).

Conclusion

Acquisition of M. catarrhalis in COPD causes increased airway inflammation and worsening protease-antiprotease imbalance during exacerbations and also in colonization, even in the absence of increased symptoms. These effects could contribute to progression of airway disease in COPD.
Appendix
Available only for authorised users
Literature
1.
go back to reference Celli BR, MacNee W: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004, 23 (6): 932-46. 10.1183/09031936.04.00014304.CrossRefPubMed Celli BR, MacNee W: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004, 23 (6): 932-46. 10.1183/09031936.04.00014304.CrossRefPubMed
2.
go back to reference Keatings VM, Collins PD, Scott DM, Barnes PJ: Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med. 1996, 153 (2): 530-4.CrossRefPubMed Keatings VM, Collins PD, Scott DM, Barnes PJ: Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med. 1996, 153 (2): 530-4.CrossRefPubMed
3.
go back to reference Riise GC, Ahlstedt S, Larsson S, Enander I, Jones I, Larsson P, et al: Bronchial inflammation in chronic bronchitis assessed by measurement of cell products in bronchial lavage fluid. Thorax. 1995, 50 (4): 360-5. 10.1136/thx.50.4.360.CrossRefPubMedPubMedCentral Riise GC, Ahlstedt S, Larsson S, Enander I, Jones I, Larsson P, et al: Bronchial inflammation in chronic bronchitis assessed by measurement of cell products in bronchial lavage fluid. Thorax. 1995, 50 (4): 360-5. 10.1136/thx.50.4.360.CrossRefPubMedPubMedCentral
4.
go back to reference Hill AT, Bayley D, Stockley RA: The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am J Respir Crit Care Med. 1999, 160 (3): 893-8.CrossRefPubMed Hill AT, Bayley D, Stockley RA: The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am J Respir Crit Care Med. 1999, 160 (3): 893-8.CrossRefPubMed
5.
go back to reference Sethi S, Wrona C, Eschberger K, Lobbins P, Cai X, Murphy TF: Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008, 177 (5): 491-7. 10.1164/rccm.200708-1234OC.CrossRefPubMed Sethi S, Wrona C, Eschberger K, Lobbins P, Cai X, Murphy TF: Inflammatory profile of new bacterial strain exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008, 177 (5): 491-7. 10.1164/rccm.200708-1234OC.CrossRefPubMed
6.
go back to reference Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, et al: Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006, 173 (10): 1114-21. 10.1164/rccm.200506-859OC.CrossRefPubMed Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, et al: Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006, 173 (10): 1114-21. 10.1164/rccm.200506-859OC.CrossRefPubMed
7.
go back to reference Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA: Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002, 57 (10): 847-52. 10.1136/thorax.57.10.847.CrossRefPubMedPubMedCentral Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA: Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002, 57 (10): 847-52. 10.1136/thorax.57.10.847.CrossRefPubMedPubMedCentral
8.
go back to reference Hill AT, Campbell EJ, Bayley DL, Hill SL, Stockley RA: Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha(1)-antitrypsin deficiency (PiZ). Am J Respir Crit Care Med. 1999, 60 (6): 1968-75.CrossRef Hill AT, Campbell EJ, Bayley DL, Hill SL, Stockley RA: Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha(1)-antitrypsin deficiency (PiZ). Am J Respir Crit Care Med. 1999, 60 (6): 1968-75.CrossRef
9.
go back to reference Sethi S, Muscarella K, Evans N, Klingman KL, Grant BJ, Murphy TF: Airway inflammation and etiology of acute exacerbations of chronic bronchitis. Chest. 2000, 118 (6): 1557-65. 10.1378/chest.118.6.1557.CrossRefPubMed Sethi S, Muscarella K, Evans N, Klingman KL, Grant BJ, Murphy TF: Airway inflammation and etiology of acute exacerbations of chronic bronchitis. Chest. 2000, 118 (6): 1557-65. 10.1378/chest.118.6.1557.CrossRefPubMed
10.
go back to reference Sethi S, Murphy TF: Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008, 359 (22): 2355-65. 10.1056/NEJMra0800353.CrossRefPubMed Sethi S, Murphy TF: Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008, 359 (22): 2355-65. 10.1056/NEJMra0800353.CrossRefPubMed
11.
go back to reference Sethi S, Evans N, Grant BJ, Murphy TF: New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 2002, 347 (7): 465-71. 10.1056/NEJMoa012561.CrossRefPubMed Sethi S, Evans N, Grant BJ, Murphy TF: New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 2002, 347 (7): 465-71. 10.1056/NEJMoa012561.CrossRefPubMed
12.
go back to reference Murphy TF, Brauer AL, Grant BJ, Sethi S: Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response. Am J Respir Crit Care Med. 2005, 172 (2): 195-9. 10.1164/rccm.200412-1747OC.CrossRefPubMedPubMedCentral Murphy TF, Brauer AL, Grant BJ, Sethi S: Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response. Am J Respir Crit Care Med. 2005, 172 (2): 195-9. 10.1164/rccm.200412-1747OC.CrossRefPubMedPubMedCentral
13.
go back to reference Hill AT, Campbell EJ, Hill SL, Bayley DL, Stockley RA: Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med. 2000, 109 (4): 288-95. 10.1016/S0002-9343(00)00507-6.CrossRefPubMed Hill AT, Campbell EJ, Hill SL, Bayley DL, Stockley RA: Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med. 2000, 109 (4): 288-95. 10.1016/S0002-9343(00)00507-6.CrossRefPubMed
14.
go back to reference Soler N, Ewig S, Torres A, Filella X, Gonzalez J, Zaubet A: Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J. 1999, 14 (5): 1015-22. 10.1183/09031936.99.14510159.CrossRefPubMed Soler N, Ewig S, Torres A, Filella X, Gonzalez J, Zaubet A: Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J. 1999, 14 (5): 1015-22. 10.1183/09031936.99.14510159.CrossRefPubMed
15.
go back to reference Bresser P, Out TA, van Alphen L, Jansen HM, Lutter R: Airway inflammation in nonobstructive and obstructive chronic bronchitis with chronic haemophilus influenzae airway infection. Comparison with noninfected patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000, 162 (3 Pt 1): 947-52.CrossRefPubMed Bresser P, Out TA, van Alphen L, Jansen HM, Lutter R: Airway inflammation in nonobstructive and obstructive chronic bronchitis with chronic haemophilus influenzae airway infection. Comparison with noninfected patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000, 162 (3 Pt 1): 947-52.CrossRefPubMed
16.
go back to reference Sethi S: Infectious etiology of acute exacerbations of chronic bronchitis. Chest. 2000, 117 (5 Suppl 2): 380S-5S. 10.1378/chest.117.5_suppl_2.380S.CrossRefPubMed Sethi S: Infectious etiology of acute exacerbations of chronic bronchitis. Chest. 2000, 117 (5 Suppl 2): 380S-5S. 10.1378/chest.117.5_suppl_2.380S.CrossRefPubMed
17.
go back to reference Gompertz S, O'Brien C, Bayley DL, Hill SL, Stockley RA: Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J. 2001, 17 (6): 1112-9. 10.1183/09031936.01.99114901.CrossRefPubMed Gompertz S, O'Brien C, Bayley DL, Hill SL, Stockley RA: Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J. 2001, 17 (6): 1112-9. 10.1183/09031936.01.99114901.CrossRefPubMed
18.
go back to reference Stockley RA: Neutrophils and protease/antiprotease imbalance. Am J Respir Crit Care Med. 1999, 160 (5 Pt 2): S49-52.CrossRefPubMed Stockley RA: Neutrophils and protease/antiprotease imbalance. Am J Respir Crit Care Med. 1999, 160 (5 Pt 2): S49-52.CrossRefPubMed
19.
go back to reference Sallenave JM, Shulmann J, Crossley J, Jordana M, Gauldie J: Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. Am J Respir Cell Mol Biol. 1994, 11 (6): 733-41.CrossRefPubMed Sallenave JM, Shulmann J, Crossley J, Jordana M, Gauldie J: Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. Am J Respir Cell Mol Biol. 1994, 11 (6): 733-41.CrossRefPubMed
20.
go back to reference van Wetering S, Linden van der AC, van Sterkenburg MA, Rabe KF, Schalkwijk J, Hiemstra PS: Regulation of secretory leukocyte proteinase inhibitor (SLPI) production by human bronchial epithelial cells: increase of cell-associated SLPI by neutrophil elastase. J Investig Med. 2000, 48 (5): 359-66.PubMed van Wetering S, Linden van der AC, van Sterkenburg MA, Rabe KF, Schalkwijk J, Hiemstra PS: Regulation of secretory leukocyte proteinase inhibitor (SLPI) production by human bronchial epithelial cells: increase of cell-associated SLPI by neutrophil elastase. J Investig Med. 2000, 48 (5): 359-66.PubMed
21.
go back to reference Abbinante-Nissen JM, Simpson LG, Leikauf GD: Neutrophil elastase increases secretory leukocyte protease inhibitor transcript levels in airway epithelial cells. Am J Physiol. 1993, 265 (3 Pt 1): L286-92.PubMed Abbinante-Nissen JM, Simpson LG, Leikauf GD: Neutrophil elastase increases secretory leukocyte protease inhibitor transcript levels in airway epithelial cells. Am J Physiol. 1993, 265 (3 Pt 1): L286-92.PubMed
22.
go back to reference Marchand V, Tournier JM, Polette M, Nawrocki B, Fuchey C, Pierrot D, et al: The elastase-induced expression of secretory leukocyte protease inhibitor is decreased in remodelled airway epithelium. Eur J Pharmacol. 1997, 336 (2-3): 187-96. 10.1016/S0014-2999(97)01222-3.CrossRefPubMed Marchand V, Tournier JM, Polette M, Nawrocki B, Fuchey C, Pierrot D, et al: The elastase-induced expression of secretory leukocyte protease inhibitor is decreased in remodelled airway epithelium. Eur J Pharmacol. 1997, 336 (2-3): 187-96. 10.1016/S0014-2999(97)01222-3.CrossRefPubMed
23.
go back to reference Saitoh H, Masuda T, Shimura S, Fushimi T, Shirato K: Secretion and gene expression of secretory leukocyte protease inhibitor by human airway submucosal glands. Am J Physiol Lung Cell Mol Physiol. 2001, 280 (1): L79-87.PubMed Saitoh H, Masuda T, Shimura S, Fushimi T, Shirato K: Secretion and gene expression of secretory leukocyte protease inhibitor by human airway submucosal glands. Am J Physiol Lung Cell Mol Physiol. 2001, 280 (1): L79-87.PubMed
24.
go back to reference Vogelmeier C, Hubbard RC, Fells GA, Schnebli HP, Thompson RC, Fritz H, et al: Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor. J Clin Invest. 1991, 87 (2): 482-8. 10.1172/JCI115021.CrossRefPubMedPubMedCentral Vogelmeier C, Hubbard RC, Fells GA, Schnebli HP, Thompson RC, Fritz H, et al: Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor. J Clin Invest. 1991, 87 (2): 482-8. 10.1172/JCI115021.CrossRefPubMedPubMedCentral
25.
go back to reference Taggart CC, Lowe GJ, Greene CM, Mulgrew AT, O'Neill SJ, Levine RL, et al: Cathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor. J Biol Chem. 2001, 276 (36): 33345-52. 10.1074/jbc.M103220200.CrossRefPubMed Taggart CC, Lowe GJ, Greene CM, Mulgrew AT, O'Neill SJ, Levine RL, et al: Cathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor. J Biol Chem. 2001, 276 (36): 33345-52. 10.1074/jbc.M103220200.CrossRefPubMed
26.
go back to reference Sullivan AL, Dafforn T, Hiemstra PS, Stockley RA: Neutrophil elastase reduces secretion of secretory leukoproteinase inhibitor (SLPI) by lung epithelial cells: role of charge of the proteinase-inhibitor complex. Respir Res. 2008, 9: 60-10.1186/1465-9921-9-60.CrossRefPubMedPubMedCentral Sullivan AL, Dafforn T, Hiemstra PS, Stockley RA: Neutrophil elastase reduces secretion of secretory leukoproteinase inhibitor (SLPI) by lung epithelial cells: role of charge of the proteinase-inhibitor complex. Respir Res. 2008, 9: 60-10.1186/1465-9921-9-60.CrossRefPubMedPubMedCentral
27.
go back to reference Stockley RA: Neutrophils and the pathogenesis of COPD. Chest. 2002, 121 (5 Suppl): 151S-5S. 10.1378/chest.121.5_suppl.151S.CrossRefPubMed Stockley RA: Neutrophils and the pathogenesis of COPD. Chest. 2002, 121 (5 Suppl): 151S-5S. 10.1378/chest.121.5_suppl.151S.CrossRefPubMed
28.
go back to reference Nadel JA: Role of Neutrophil Elastase in Hypersecretion During COPD Exacerbations, and Proposed Therapies*. Chest. 2000, 117 (5 suppl 2): 386S-9S. 10.1378/chest.117.5_suppl_2.386S.CrossRefPubMed Nadel JA: Role of Neutrophil Elastase in Hypersecretion During COPD Exacerbations, and Proposed Therapies*. Chest. 2000, 117 (5 suppl 2): 386S-9S. 10.1378/chest.117.5_suppl_2.386S.CrossRefPubMed
29.
go back to reference Murphy TF, Brauer AL, Aebi C, Sethi S: Antigenic specificity of the mucosal antibody response to Moraxella catarrhalis in chronic obstructive pulmonary disease. Infect Immun. 2005, 73 (12): 8161-6. 10.1128/IAI.73.12.8161-8166.2005.CrossRefPubMedPubMedCentral Murphy TF, Brauer AL, Aebi C, Sethi S: Antigenic specificity of the mucosal antibody response to Moraxella catarrhalis in chronic obstructive pulmonary disease. Infect Immun. 2005, 73 (12): 8161-6. 10.1128/IAI.73.12.8161-8166.2005.CrossRefPubMedPubMedCentral
30.
go back to reference Murphy TF, Brauer AL, Aebi C, Sethi S: Identification of surface antigens of Moraxella catarrhalis as targets of human serum antibody responses in chronic obstructive pulmonary disease. Infect Immun. 2005, 73 (6): 3471-8. 10.1128/IAI.73.6.3471-3478.2005.CrossRefPubMedPubMedCentral Murphy TF, Brauer AL, Aebi C, Sethi S: Identification of surface antigens of Moraxella catarrhalis as targets of human serum antibody responses in chronic obstructive pulmonary disease. Infect Immun. 2005, 73 (6): 3471-8. 10.1128/IAI.73.6.3471-3478.2005.CrossRefPubMedPubMedCentral
31.
go back to reference Slevogt H, Schmeck B, Jonatat C, Zahlten J, Beermann W, van Laak V, et al: Moraxella catarrhalis induces inflammatory response of bronchial epithelial cells via MAPK and NF-kappaB activation and histone deacetylase activity reduction. Am J Physiol Lung Cell Mol Physiol. 2006, 290 (5): L818-26. 10.1152/ajplung.00428.2005.CrossRefPubMed Slevogt H, Schmeck B, Jonatat C, Zahlten J, Beermann W, van Laak V, et al: Moraxella catarrhalis induces inflammatory response of bronchial epithelial cells via MAPK and NF-kappaB activation and histone deacetylase activity reduction. Am J Physiol Lung Cell Mol Physiol. 2006, 290 (5): L818-26. 10.1152/ajplung.00428.2005.CrossRefPubMed
32.
go back to reference Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, et al: Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med. 2005, 352 (19): 1967-76. 10.1056/NEJMoa041892.CrossRefPubMed Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, et al: Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med. 2005, 352 (19): 1967-76. 10.1056/NEJMoa041892.CrossRefPubMed
Metadata
Title
Moraxella catarrhalisacquisition, airway inflammation and protease-antiprotease balance in chronic obstructive pulmonary disease
Authors
Ganapathi I Parameswaran
Catherine T Wrona
Timothy F Murphy
Sanjay Sethi
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2009
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-9-178

Other articles of this Issue 1/2009

BMC Infectious Diseases 1/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine